Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.53
APRI's Cash to Debt is ranked lower than
56% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.35 vs. APRI: 1.53 )
Ranked among companies with meaningful Cash to Debt only.
APRI' s 10-Year Cash to Debt Range
Min: 0.03  Med: 2.10 Max: No Debt
Current: 1.53
Equity to Asset -0.29
APRI's Equity to Asset is ranked lower than
98% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. APRI: -0.29 )
Ranked among companies with meaningful Equity to Asset only.
APRI' s 10-Year Equity to Asset Range
Min: -0.29  Med: 0.45 Max: 0.87
Current: -0.29
-0.29
0.87
F-Score: 2
Z-Score: -42.64
M-Score: 10.20
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -679.16
APRI's Operating margin (%) is ranked lower than
95% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.92 vs. APRI: -679.16 )
Ranked among companies with meaningful Operating margin (%) only.
APRI' s 10-Year Operating margin (%) Range
Min: -25298.53  Med: -571.73 Max: -86.86
Current: -679.16
-25298.53
-86.86
Net-margin (%) -676.04
APRI's Net-margin (%) is ranked lower than
96% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.96 vs. APRI: -676.04 )
Ranked among companies with meaningful Net-margin (%) only.
APRI' s 10-Year Net-margin (%) Range
Min: -23786.76  Med: -643.68 Max: -83.71
Current: -676.04
-23786.76
-83.71
ROE (%) -662.85
APRI's ROE (%) is ranked lower than
99% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.43 vs. APRI: -662.85 )
Ranked among companies with meaningful ROE (%) only.
APRI' s 10-Year ROE (%) Range
Min: -1512.53  Med: -197.42 Max: -38.69
Current: -662.85
-1512.53
-38.69
ROA (%) -186.56
APRI's ROA (%) is ranked lower than
99% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. APRI: -186.56 )
Ranked among companies with meaningful ROA (%) only.
APRI' s 10-Year ROA (%) Range
Min: -217.31  Med: -91.90 Max: -37.07
Current: -186.56
-217.31
-37.07
ROC (Joel Greenblatt) (%) -2334.44
APRI's ROC (Joel Greenblatt) (%) is ranked lower than
93% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.24 vs. APRI: -2334.44 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
APRI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2232.26  Med: -257.18 Max: -67.95
Current: -2334.44
-2232.26
-67.95
Revenue Growth (3Y)(%) 4.80
APRI's Revenue Growth (3Y)(%) is ranked lower than
53% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. APRI: 4.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
APRI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 4.80 Max: 105.1
Current: 4.8
0
105.1
EBITDA Growth (3Y)(%) -12.80
APRI's EBITDA Growth (3Y)(%) is ranked lower than
75% of the 494 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. APRI: -12.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
APRI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -17.30 Max: 49.9
Current: -12.8
0
49.9
EPS Growth (3Y)(%) -14.10
APRI's EPS Growth (3Y)(%) is ranked lower than
72% of the 455 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. APRI: -14.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
APRI' s 10-Year EPS Growth (3Y)(%) Range
Min: -44.3  Med: -14.40 Max: 78.2
Current: -14.1
-44.3
78.2
» APRI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

APRI Guru Trades in

Q4 2014

APRI Guru Trades in Q4 2014

Jim Simons 53,629 sh (New)
» More
Q1 2015

APRI Guru Trades in Q1 2015

Charles Brandes 53,500 sh (New)
Jim Simons Sold Out
» More
Q2 2015

APRI Guru Trades in Q2 2015

Charles Brandes 53,500 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with APRI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 16.74
APRI's P/S is ranked lower than
86% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. APRI: 16.74 )
Ranked among companies with meaningful P/S only.
APRI' s 10-Year P/S Range
Min: 0.78  Med: 15.02 Max: 1380
Current: 16.74
0.78
1380
Current Ratio 1.97
APRI's Current Ratio is ranked lower than
59% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. APRI: 1.97 )
Ranked among companies with meaningful Current Ratio only.
APRI' s 10-Year Current Ratio Range
Min: 0.12  Med: 2.37 Max: 85.68
Current: 1.97
0.12
85.68
Quick Ratio 1.89
APRI's Quick Ratio is ranked higher than
55% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. APRI: 1.89 )
Ranked among companies with meaningful Quick Ratio only.
APRI' s 10-Year Quick Ratio Range
Min: 0.12  Med: 2.34 Max: 85.68
Current: 1.89
0.12
85.68
Days Inventory 73.74
APRI's Days Inventory is ranked higher than
70% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 111.99 vs. APRI: 73.74 )
Ranked among companies with meaningful Days Inventory only.
APRI' s 10-Year Days Inventory Range
Min: 5.45  Med: 17.21 Max: 121.47
Current: 73.74
5.45
121.47
Days Sales Outstanding 51.11
APRI's Days Sales Outstanding is ranked higher than
68% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.80 vs. APRI: 51.11 )
Ranked among companies with meaningful Days Sales Outstanding only.
APRI' s 10-Year Days Sales Outstanding Range
Min: 8.58  Med: 32.69 Max: 488.31
Current: 51.11
8.58
488.31

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.07
APRI's Price/Median PS Value is ranked higher than
80% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. APRI: 1.07 )
Ranked among companies with meaningful Price/Median PS Value only.
APRI' s 10-Year Price/Median PS Value Range
Min: 0.1  Med: 1.17 Max: 158.33
Current: 1.07
0.1
158.33
Earnings Yield (Greenblatt) (%) -37.62
APRI's Earnings Yield (Greenblatt) (%) is ranked lower than
97% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. APRI: -37.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
APRI' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -55.32  Med: 0.00 Max: 0
Current: -37.62
-55.32
0

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 3 10 11
EPS($) -0.47 -0.38 -0.35
EPS without NRI($) -0.47 -0.38 -0.35

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:NXEN.Germany,
Apricus Biosciences Inc was incorporated in Nevada in 1987. It is a pharmaceutical company, that develops and commercializes pharmaceutical products that treat large patient populations with operations based in the United States. Its products have been developed utilizing its NexACT proprietary permeation enhancement technology. Its initial approved product is Vitaros approved in Canada for the treatment of erectile dysfunction (ED) and its next in-line late stage product candidate is Femprox for the treatment of female sexual arousal disorder (FSAD). It has also filed for approval of Vitaros for the treatment of ED in Europe through the Decentralized Approval Process (DCP) and in Switzerland. Femprox has completed one Phase III clinical trial in China and the Company is developing a regulatory submission plan for additional clinical trials in the U.S., Canada and Europe. The Company operates in a single segment, through which it design and develop pharmaceutical products with our NexACT platform. On December 14, 2009, the Company acquired Bio-Quant, Inc. (Bio-Quant), a specialty biotech contract research organization (CRO) based in San Diego, California. It own an approximate total of 83 registered trademarks as well as 65 pending trademark applications and 5 allowed pending trademark applications worldwide. It owns registered trademarks for Vitaros, Femprox and NexACT in certain countries and territories.
» More Articles for NAS:APRI

Headlines

Articles On GuruFocus.com
CEO and CFO Buys Weekly Update May 29 2013 

More From Other Websites
Apricus (APRI) Shares March Higher, Can It Continue? Sep 02 2015
Apricus Biosciences to Present at the Rodman & Renshaw 17th Annual Global Investment Conference Sep 02 2015
Apricus Biosciences to Present at the Rodman & Renshaw 17th Annual Global Investment Conference Sep 02 2015
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in... Sep 01 2015
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in... Sep 01 2015
Apricus Biosciences (APRI) Looks Good: Stock Gains 9.8% Aug 31 2015
5 Big FDA Decisions Expected in September Aug 29 2015
Apricus Biosciences (APRI) in Focus: Stock Jumps 7% Aug 20 2015
Apricus Biosciences Announces it is Seeking a Global Partner for Femprox, a Novel Treatment for... Aug 19 2015
Apricus Biosciences Announces it is Seeking a Global Partner for Femprox, a Novel Treatment for... Aug 19 2015
APRICUS BIOSCIENCES, INC. Financials Aug 13 2015
APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial... Aug 10 2015
Apricus Biosciences Announces Approval of Vitaros(R) for the Treatment of Erectile Dysfunction in... Aug 10 2015
Apricus Biosciences Announces Approval of Vitaros(R) for the Treatment of Erectile Dysfunction in... Aug 10 2015
10-Q for Apricus Biosciences, Inc. Aug 07 2015
Edited Transcript of APRI earnings conference call or presentation 5-Aug-15 9:00pm GMT Aug 06 2015
Apricus reports 2Q loss Aug 05 2015
Apricus reports 2Q loss Aug 05 2015
Apricus Biosciences Inc Earnings Call scheduled for 5:00 pm ET today Aug 05 2015
Apricus Biosciences Provides Corporate Update and Second Quarter 2015 Financial Results Aug 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK